Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity

FEBS Letters

Volumn 583, Issue 22, 2009, Pages 3569-3576

  Ferreira, Nelson ^a,b   Cardoso, Isabel ^a   Domingues, Maria Rosário ^c   Vitorino, Rui ^c   Bastos, Margarida ^b   Bai, Guangyue ^b   Saraiva, Maria João ^a,b   Almeida, Maria Rosário ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

( ) Epigallocatechin 3 gallate; Aggregation; Amyloid; Transthyretin

Indexed keywords

CATECHIN; EPIGALLOCATECHIN GALLATE; PREALBUMIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG PROTEIN BINDING; EX VIVO STUDY; FAMILIAL AMYLOID POLYNEUROPATHY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; RAT; TEA;

AMINO ACID SUBSTITUTION; AMYLOID; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CATECHIN; CELL LINE; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MUTATION; PREALBUMIN; PROTEIN BINDING; PROTEIN CONFORMATION; THYROXINE; TRANSFECTION;

EID: 71749085436     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.10.062     Document Type: Article

References (31)

1. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., and Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured off-pathway oligomers. Nat. Struct. Mol. Biol. 15 (2008) 558-566
2. Hauber I., Hohenberg H., Holstermann B., Hunstein W., and Hauber J. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc. Natl. Acad. Sci. USA 106 22 (2009) 9033-9038
3. Benson M.D., and Kincaid J.C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36 (2007) 411-423
4. Saraiva M.J., Birken S., Costa P.P., and Goodman D.S. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Invest. 74 (1984) 104-119
5. Cardoso I., Goldsbury C.S., Müller S.A., Olivieri V., Wirtz S., Damas A.M., Aebi U., and Saraiva M.J. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J. Mol. Biol. 317 (2002) 683-695
6. Redondo C., Damas A.M., Olofsson A., Lundgren E., and Saraiva M.J. Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J. Mol. Biol. 304 (2000) 461-470
7. Quintas A., Saraiva M.J., and Brito R.M. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett. 418 (1997) 297-300
8. Blake C.C., Geisow M.J., Oatley S.J., Rerat B., and Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J. Mol. Biol. 121 (1978) 339-356
9. McCutchen S.L., Lai Z., Miroy G.J., Kelly J.W., and Colón W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34 41 (1995) 13527-13536
10. Quintas A., Vaz D.C., Cardoso I., Saraiva M.J., and Brito R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276 29 (2001) 27207-27213
11. Almeida M.R., Gales L., Damas A.M., Cardoso I., and Saraiva M.J. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 587-596
12. Baures P.W., Oza V.B., Peterson S.A., and Kelly J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem. 7 (1999) 1339-1347
13. 4, and decreases serum thyrotropin in the rat. Endocrinology 126 (1990) 2890-2895
14. Maia F., Almeida M.R., Gales L., Kijjoa A., Pinto M.M., Saraiva M.J., and Damas A.M. The binding of xanthone derivatives to transthyretin. Biochem. Pharmacol. 70 (2005) 1861-1869
15. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., Ehrhart J., Townsend K., Zeng J., Morgan D., Hardy J., Town T., and Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25 (2005) 8807-8814
16. Almeida M.R., Macedo B., Cardoso I., Alves I., Valencia G., Arsequell G., Planas A., and Saraiva M.J. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J. 381 (2004) 351-356
17. Paz M.A., Flückiger R., Boak A., Kagan H.M., and Gallop P.M. Specific detection of quinoproteins by redox-cycling staining. J. Biol. Chem. 266 (1991) 689-692
18. Bai G., Santos L.M.N.B.F., Nichifor M., Lopes A., and Bastos M. Thermodynamics of interaction between hydrophobically modified polyelectrolyte and sodium dodecyl sulfate in aqueous solution. J. Phys. Chem. B 108 (2004) 405-413
19. Bastos M., Hägg S., Lönnbro P., and Wadsö I. Fast titration experiments using heat conduction microcalorimeters. J. Biochem. Biophys. Meth. 23 (1991) 255-258
20. Altland K., Winter P., and Sauerborn M.K. Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradients. Electrophoresis 20 (1999) 1349-1364
21. Cardoso I., Almeida M.R., Ferreira N., Arsequell G., Valencia G., and Saraiva M.J. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem. J. 408 (2007) 131-138
22. Ishii T., Mori T., Tanaka T., Mizuno D., Yamaji R., Kumazawa S., Nakayama T., and Akagawa M. Covalent modification of proteins by green tea polyphenol (-)-epigallocatechin-3-gallate through autoxidation. Free Radic. Biol. Med. 45 (2008) 1384-1394
23. Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C., and Kelly J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 93 (1996) 15051-15056
24. Rambold A.S., Miesbauer M., Olschewski D., Seidel R., Riemer C., Smale L., Brumm L., Levy M., Gazit E., Oesterhelt D., Baier M., Becker C.F., Engelhard M., Winklhofer K.F., and Tatzelt J. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J. Neurochem. 107 (2008) 218-229
25. Ullmann U., Haller J., Decourt J.P., Girault N., Girault J., Richard-Caudron A.S., Pineau B., and Weber P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res. 31 2 (2003) 88-101
26. Chow H.H., Cai Y., Hakim I.A., Crowell J.A., Shahi F., Brooks C.A., Dorr R.T., Hara Y., and Alberts D.S. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 9 9 (2003) 3312-3319
27. Maiti T.K., Ghosh K.S., and Dasgupta S. Interaction of (-)-epigallocatechin-3-gallate with human serum albumin: fluorescence, Fourier transform infrared, circular dichroism, and docking studies. Proteins 64 (2006) 355-362
28. Kohno K., Palha J.A., Miyakawa K., Saraiva M.J., Ito S., Mabuchi T., Blaner W.S., Iijima H., Tsukahara S., Episkopou V., Gottesman M.E., Shimada K., Takahashi K., Yamamura K., and Maeda S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am. J. Pathol. 150 (1997) 1497-1508
29. Lin L.C., Wang M.N., Tseng T.Y., Sung J.S., and Tsai T.H. Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J. Agric. Food Chem. 55 (2007) 1517-1524
30. Jacobsson B., Collins V.P., Grimelius L., Pettersson T., Sandstedt B., and Carlström A. Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. J. Histochem. Cytochem. 37 (1989) 31-37
31. Nakagawa K., Sheikh S.I., Snuderl M., Frosch M.P., and Greenberg S.M. A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. J. Neurol. Sci. 272 (2008) 186-190